{
  "relevance_rule": {},
  "priority_rules": [
    {
      "priority": "High",
      "rule_text": "ENPP3, DLL3, KRAS-G12C or Pan-RAS or Pan-KRAS or KRAS-G12D and solid tumors, EGFR degrader or PROTAC, Oncolytic virus or oHSV or adenovirus and NSCLC, Radioenhancers or Radioligands or Radiotherapeutics or RLT and NSCLC",
      "approach": "keywords",
      "key_concepts": {
        "keywords": [
          "ENPP3",
          "DLL3",
          "KRAS-G12C",
          "Pan-RAS",
          "Pan-KRAS",
          "KRAS-G12D",
          "EGFR degrader",
          "PROTAC",
          "Oncolytic virus",
          "oHSV",
          "adenovirus",
          "Radioenhancer",
          "Radioligands",
          "Radiotherapeutics",
          "RLT",
          "NSCLC",
          "solid tumors"
        ],
        "categories": [
          "High Priority Targets",
          "NSCLC",
          "Solid Tumors"
        ],
        "contextual_concepts": []
      },
      "exclusions": [
        "SCLC",
        "Squamous NSCLC",
        "Mesothelin",
        "TAOK1",
        "PTK7",
        "CRAF degrader",
        "PD-1/IL-2",
        "IL-2/PD-1",
        "PD-1/IL-15",
        "IL-15/PD-1",
        "Volrustomig",
        "MEDI5752",
        "Rivelgostomig",
        "AZD-2936",
        "AZD2936",
        "BNT327",
        "BNT-327",
        "PM8002",
        "SSGJ-707",
        "IBI-363",
        "IBI363",
        "Any new targets for squamous NSCLC",
        "Any new targets for SCLC"
      ],
      "reasoning": "This rule is based on direct keyword matching from the client keywords and is mutually exclusive from the Medium priority rule by excluding all Medium priority concepts."
    },
    {
      "priority": "Medium",
      "rule_text": "Volrustomig or MEDI5752 or MEDI-5752, Rivelgostomig or AZD-2936 or AZD2936, BNT327 or BNT-327 or PM8002, SSGJ-707, IBI-363 or IBI363, PD-1/IL-2 or IL-2/PD-1, PD-1/IL-15 or IL-15/PD-1, Mesothelin or MSLN, TAOK1, PTK7 or PTK-7, CRAF degrader, EGFR degrader, any new targets for squamous NSCLC, any new targets for SCLC",
      "approach": "keywords",
      "key_concepts": {
        "keywords": [
          "Volrustomig",
          "MEDI5752",
          "MEDI-5752",
          "Rivelgostomig",
          "AZD-2936",
          "AZD2936",
          "BNT327",
          "BNT-327",
          "PM8002",
          "SSGJ-707",
          "IBI-363",
          "IBI363",
          "PD-1/IL-2",
          "IL-2/PD-1",
          "PD-1/IL-15",
          "IL-15/PD-1",
          "Mesothelin",
          "MSLN",
          "TAOK1",
          "PTK7",
          "PTK-7",
          "CRAF degrader",
          "EGFR degrader",
          "Any new targets for squamous NSCLC",
          "Any new targets for SCLC"
        ],
        "categories": [
          "Medium Priority Targets",
          "Squamous NSCLC",
          "SCLC"
        ],
        "contextual_concepts": []
      },
      "exclusions": [
        "ENPP3",
        "DLL3",
        "KRAS-G12C",
        "Pan-RAS",
        "Pan-KRAS",
        "KRAS-G12D",
        "Oncolytic virus",
        "oHSV",
        "adenovirus",
        "Radioenhancer",
        "Radioligands",
        "Radiotherapeutics",
        "RLT",
        "NSCLC",
        "solid tumors"
      ],
      "reasoning": "This rule is based on direct keyword matching from the client keywords and excludes all High priority concepts to ensure mutual exclusivity."
    }
  ]
}